Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
24
01
2019
accepted:
22
08
2019
pubmed:
24
8
2019
medline:
28
4
2021
entrez:
24
8
2019
Statut:
ppublish
Résumé
Innate drug sensitivity in healthy cells aids identification of lineage specific anti-cancer therapies and reveals off-target effects. To characterize the diversity in drug responses in the major hematopoietic cell types, we simultaneously assessed their sensitivity to 71 small molecules utilizing a multi-parametric flow cytometry assay and mapped their proteomic and basal signaling profiles. Unsupervised hierarchical clustering identified distinct drug responses in healthy cell subsets based on their cellular lineage. Compared to other cell types, CD19
Identifiants
pubmed: 31439679
pii: haematol.2019.217414
doi: 10.3324/haematol.2019.217414
pmc: PMC7271564
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1527-1538Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Leukemia. 2018 Mar;32(3):774-787
pubmed: 28804127
Drugs Today (Barc). 2017 Oct;53(10):531-543
pubmed: 29286055
Int Rev Immunol. 2013 Aug;32(4):358-76
pubmed: 23617253
Curr Hematol Malig Rep. 2017 Jun;12(3):207-216
pubmed: 28439761
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Exp Hematol. 1993 Feb;21(2):303-10
pubmed: 7678814
Leukemia. 2012 Jun;26(6):1255-65
pubmed: 22282267
Nat Rev Cancer. 2006 Feb;6(2):146-55
pubmed: 16491074
J Hematol Oncol. 2015 Nov 20;8:129
pubmed: 26589495
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2028-33
pubmed: 18250324
Leukemia. 2017 Feb;31(2):301-309
pubmed: 27499136
Cancer Discov. 2013 Dec;3(12):1416-29
pubmed: 24056683
Nat Biotechnol. 2012 Sep;30(9):858-67
pubmed: 22902532
Blood. 2012 Oct 25;120(17):3397-406
pubmed: 22898602
Cell. 2004 Jul 23;118(2):217-28
pubmed: 15260991
Blood Adv. 2018 Feb 27;2(4):444-453
pubmed: 29487059
Oncotarget. 2017 May 5;8(34):56338-56350
pubmed: 28915594
Sci Transl Med. 2016 Aug 31;8(354):354ra114
pubmed: 27582059
Nat Chem Biol. 2008 Feb;4(2):132-42
pubmed: 18157122
J Blood Med. 2016 Apr 19;7:73-83
pubmed: 27186148
J Clin Endocrinol Metab. 2015 Feb;100(2):E232-42
pubmed: 25423568
Blood. 2017 Dec 7;130(23):2499-2503
pubmed: 28972014
Cell Rep. 2017 Dec 12;21(11):3285-3297
pubmed: 29241553
PLoS One. 2014 May 12;9(5):e97242
pubmed: 24820971
Nature. 2017 Feb 23;542(7642):489-493
pubmed: 28199309
Free Radic Biol Med. 2011 Dec 1;51(11):2048-59
pubmed: 21964507
Oncotarget. 2017 Apr 4;8(14):23564-23574
pubmed: 28423597
Onco Targets Ther. 2016 Aug 08;9:4887-99
pubmed: 27540302
JAKSTAT. 2013 Oct 1;2(4):e25256
pubmed: 24416646
Leukemia. 2017 Jan;31(1):51-57
pubmed: 27461063
BMC Immunol. 2015 Aug 28;16:50
pubmed: 26315539
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
Am J Ther. 2007 Sep-Oct;14(5):488-98
pubmed: 17890940
J Oncol Pract. 2017 Jun;13(6):371-377
pubmed: 28605616
Oncotarget. 2017 Apr 4;8(14):22606-22615
pubmed: 28186983
Haematologica. 2002 Feb;87(2):167-76
pubmed: 11836167
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Anticancer Agents Med Chem. 2009 Nov;9(9):1024-38
pubmed: 19663778
Haematologica. 2015 Oct;100(10):1240-53
pubmed: 26432382
Cancer Res. 2001 Mar 15;61(6):2766-73
pubmed: 11289160
Semin Hematol. 2003 Jul;40(3):221-32
pubmed: 12876671
Pediatr Blood Cancer. 2016 Aug;63(8):1457-60
pubmed: 27093190
Sci Rep. 2014 Jun 05;4:5193
pubmed: 24898935
Blood Cancer J. 2015 May 01;5:e309
pubmed: 25933373
Front Immunol. 2017 Aug 14;8:950
pubmed: 28855903
Blood. 2017 Aug 10;130(6):789-802
pubmed: 28619982